Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Danaparoid sodium (Primary) ; Argatroban
- Indications Heparin-induced thrombocytopenia and thrombosis syndrome
- Focus Registrational; Therapeutic Use
- Acronyms HITSOVA
- Sponsors Aspen Pharmacare
Most Recent Events
- 06 Dec 2022 Status changed from active, no longer recruiting to discontinued.
- 14 Jul 2022 This trial has been discontinued in Czechia (end date of the trial : 10-Jun-2022), according to European Clinical Trials Database record.
- 07 Jul 2022 This trial has been discontinued in France (Date of the global end of the trial : 10-Jun-2022), according to European Clinical Trials Database record.